ArticleBioengineering (Basel, Switzerland)2025
Automatic 3D Tracking of Liver Metastases: Follow-Up Assessment of Cancer Patients in Contrast-Enhanced MRI.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTracking differential growth of secondary liver metastases is important for early detection of progression but remains challenging due to variable tumor growth rates. We aimed to automate accurate, consistent, and efficient longitudinal monitoring.
methodsWe developed an automatic 3D segmentation and tracking algorithm to quantify differential growth, tested on contrast-enhanced MRI follow-ups of patients with neuroendocrine liver metastases (NELMs). The output was integrated into a decision support tool to distinguish between progressive disease, stable disease, and partial/complete response. A user study involving an expert group of seven expert radiologists evaluated its impact. Group comparisons used the Friedman test with post hoc analyses.
resultsOur algorithm detected 991 metastases in 30 patients: 13% new, 30% progressive, 18% stable, and 18% regressive; the remainder were either too small to measure (15%) or merged with another metastasis in the follow-up assessment (6%). Diagnostic accuracy improved with additional information on hepatic tumor load and differential growth, albeit not significantly (
conclusionsWe automated segmentation and quantification of individual NELMs, enabling comprehensive longitudinal analysis of differential tumor growth with the potential to enhance clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.